BioNTech Tumbles 8% as Colorectal Cancer Vaccine Trial Fails, Moderna Drops 6%, Pfizer Holds Flat
BioNTech's colorectal cancer vaccine just collapsed in a Phase 2 trial, dragging Moderna down with it despite last week's melanoma triumph, and the fallout is forcing investors to rethink how far mRNA technology can actually reach into solid tumors.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
A single trial readout is reshuffling the mRNA vaccine trade this morning. BioNTech SE (NASDAQ:BNTX | BNTX Price Prediction) stock is down 8% to $102.38 after the company terminated its Phase 2 colorectal cancer vaccine trial for futility, ending one of the highest-profile programs in its post-COVID oncology pivot.
The read-across is hitting the platform peer group. Moderna (NASDAQ:MRNA) stock is down 6% to $134.48 as investors trim exposure to mRNA cancer vaccines, while Pfizer (NYSE:PFE) stock is down 0.4% to $27.91 and largely insulated from the oncology setback despite its BioNTech partnership on COVID shots. The SPDR S&P 500 ETF Trust (NYSEARCA:SPY) is up 0.45% at $774.57, but the evidence suggests that the move in BNTX is company-specific.
Colorectal Vaccine Termination Guts the Oncology Thesis
BioNTech stopped its Phase 2 BNT122-01 study of autogene cevumeran, an mRNA cancer vaccine developed with Genentech, which was testing the shot as adjuvant monotherapy in patients with surgically resected, high-risk Stage II/III colorectal cancer. An independent Data Safety Monitoring Board flagged a numerical imbalance in overall survival between the treatment arms and concluded that continuing the trial would not change the efficacy outcome.
The futility boundary was actually crossed back in October 2025, though the underlying dataset was initially deemed too immature to halt the study at that point. BioNTech continued to blind the trial as investigators awaited additional survival events, and the follow-up analysis confirmed the earlier signal. Chief Medical Officer Prof. Özlem Türeci stated the outcome “provides scientific insight into the challenges of treating immunotherapy-insensitive tumor types with immune-suppressive microenvironments.”
The termination reverses part of an otherwise strong summer for BioNTech shares, which had climbed 17% year to date through Thursday’s close. The consensus analyst target still sits at $121.16, leaving the sell side with a gap to reconcile as models absorb the removal of a marquee oncology asset.
Why Moderna’s Melanoma Win Doesn’t Rescue the Read
Moderna and Merck reported a Phase 3 success last week for their mRNA vaccine combined with Keytruda in melanoma, and Moderna stock more than doubled in a single session on August 19. Melanoma is an immunologically hot tumor with a high mutational burden that already responds well to immunotherapy, while colorectal cancer is immunologically cold and has historically resisted immune-based treatment. That biological gap is why yesterday’s readout doesn’t automatically undermine Moderna’s melanoma franchise, even as it forces a re-underwriting of the mRNA cancer vaccine class as a whole.
The trial designs also diverge in a way that matters for the read. Moderna tested a combination with an established checkpoint inhibitor, while BioNTech tested a standalone monotherapy against watchful waiting, a significantly higher clinical hurdle. No Moderna-specific catalyst has been verified for today’s session, so the Moderna stock decline likely reflects a mix of platform read-across and profit taking.
Pfizer Barely Budges as Seasonal COVID Approval Cushions the Spillover
Separately, the FDA approved Pfizer and BioNTech’s 2026-2027 COVID-19 vaccine formula targeting the XFG variant on Thursday, for adults 65 and older and for people aged 5 through 64 with at least one high-risk underlying condition. Shipping begins immediately. The approval matters more for the seasonal revenue split between the two partners than for either stock’s long-term trajectory.
For Pfizer, this is routine seasonal business layered on top of a diversified oncology and specialty franchise that spans Padcev, Ibrance, Xtandi, and Lorbrena, which is why Pfizer shares are barely budging today. For BioNTech, the seasonal approval isn’t large enough to offset the loss of a flagship oncology asset that helped anchor the post-COVID growth narrative.
BioNTech’s balance sheet does soften the blow operationally. The company reported €16.6 billion in cash and securities in the second quarter of 2026 against a net loss of €820.8 million for the quarter, so isolated program failures don’t threaten funding for the rest of the pipeline, including the Phase 2 IMcode003 pancreatic cancer trial that combines the platform with checkpoint blockade and chemotherapy.
What to Watch Next
An interim analysis of the BNT113 head and neck cancer trial is upcoming, and the ESMO Congress in October 2026 may offer side-by-side data from both companies. That backdrop gives the market a cleaner benchmark to judge whether individualized neoantigen vaccines can travel beyond melanoma into harder tumor types.
BioNTech shareholders should consider right-sizing their positions given the pipeline gap now exposed, and Moderna holders may want to review their exposure after a parabolic month that leaves the valuation stretched relative to the $104.53 average analyst target. Traders can watch for a stabilization bid in BioNTech shares once forced-seller and arbitrage flows finish resetting.
Contact [email protected] for any questions or corrections.
David Moadel is financial writer specializing in stocks, ETFs, options, precious metals, and Bitcoin. David has written well over 1,000 articles for leading online publications, helping investors understand markets, income strategies, and risk.
His work has appeared in The Motley Fool, InvestorPlace, U.S. News & World Report, TipRanks, ValueWalk, Benzinga, Market Realist, TalkMarkets, Finmasters, 24/7 Wall St., and others.
With a master’s degree in education, David has taught at the elementary, high school, and college levels. That teaching background shapes his writing style: clear, educational, and practical. David has also built a loyal social-media audience by providing trustworthy financial content on YouTube, X/Twitter, and StockTwits.
